The clinical utility of genomic profiling in risperidone pharmacotherapy was discussed in Pharmacogenomics and Personalized Medicine “CYP2D6 polymorphisms and their influence on risperidone treatment” (Dec 2016). Risperidone (Risperidal) is an atypical antipsychotic (AAP) drug that is indicated for the treatment of autism, schizophrenia, and acute bipolar mania. It exerts its pharmacologic effects by binding to and inhibiting serotonin and dopamine receptors.
Risperidone is metabolized by hepatic metabolism via the CYP2D6 enzymatic pathway to its major active metabolite 9-hydroxyrisperidone and therapeutic response and likelihood of risperidone side effects based on plasma concentrations of risperidone and its metabolite. According to the investigators, several studies suggested that CYP2D6 polymorphisms were associated with these plasma concentration. Hence, CYP2D6 poor metabolizers showed more serious adverse events such as weight gain and prolactin than other predicted phenotype groups.
According to researchers, “As the knowledge of pharmacogenomics of CYP2D6 in risperidone treatment is increasing, it can be used for the development of personalized medication in term of genetic-based dose recommendation,” and advocated for future research into genetic-based risperidone treatment.